FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James McKenney

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Mark J Cziraky; Maxine D Fisher; John R Guyton; Terry A Jacobson; Siddhesh A Kamat; James M McKenney; Vincent J Willey; Michael H Davidson
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
Eli M Roth; Gaelle Asset; Corinne Hanotin; James M McKenney; Evan A Stein
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
James M McKenney; Anne-Catherine Ferrand; Corinne Hanotin; Dean J Kereiakes; Michael J Koren; Evan A Stein
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James McKenney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mark J Cziraky; Maxine D Fisher; John R Guyton; Terry A Jacobson; Siddhesh A Kamat; James M McKenney; Vincent J Willey; Michael H Davidson
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
Journal of clinical lipidology 2013;7(2):102-8.
2012: Eli M Roth; Gaelle Asset; Corinne Hanotin; James M McKenney; Evan A Stein
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
The New England journal of medicine 2012;367(20):1891-900.
2012: James M McKenney; Anne-Catherine Ferrand; Corinne Hanotin; Dean J Kereiakes; Michael J Koren; Evan A Stein
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
Journal of the American College of Cardiology 2012;59(25):2344-53.
2008: Pritti Gosai; Jianhua Liu; Ralph T Doyle; Judith Johnson; Roderick Carter; Domenic Sica; James M McKenney
Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults.
Expert opinion on pharmacotherapy 2008;9(17):2947-53.
2008: Christie M Ballantyne; Michael H Davidson; James M McKenney; Laurence H Keller; Daiva Regina Bajorunas; Richard H Karas
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.
Journal of clinical lipidology 2008;2(2):79-90.
2007: James M McKenney; Peter H Jones; Harold E Bays; Robert H Knopp; Moti L Kashyap; Gary E Ruoff; Mark E McGovern
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Atherosclerosis 2007;192(2):432-7.
2007: James M McKenney; Domenic A Sica
Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
Pharmacotherapy 2007;27(5):715-28.
2007: Terry A Jacobson; Annemarie Armani; James M McKenney; John R Guyton
Safety considerations with gastrointestinally active lipid-lowering drugs.
The American journal of cardiology 2007;99(6A):47C-55C.
2007: Michael H Davidson; Annemarie Armani; James M McKenney; Terry A Jacobson
Safety considerations with fibrate therapy.
The American journal of cardiology 2007;99(6A):3C-18C.
2007: James M McKenney; Domenic A Sica
Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2007;64(6):595-605.
2007: James M McKenney
Effect of drugs on high-density lipoprotein.
Journal of clinical lipidology 2007;1(1):74-87.
2006: James M McKenney; Michael H Davidson; Charles L Shear; James H Revkin
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
Journal of the American College of Cardiology 2006;48(9):1782-90.
2006: Michael H Davidson; James M McKenney; Charles L Shear; James H Revkin
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Journal of the American College of Cardiology 2006;48(9):1774-81.
2006: James M McKenney; Michel Farnier; Kwok-Wing Lo; Harold E Bays; Inna Perevozkaya; Gary Carlson; Michael J Davies; Yale B Mitchel; Barry Gumbiner
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
Journal of the American College of Cardiology 2006;47(8):1584-7.
2006: James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
The American journal of cardiology 2006;97(8A):89C-94C.
2006: Mark J Cziraky; Vincent J Willey; James M McKenney; Siddhesh Kamat; Maxine D Fisher; John R Guyton; Terry A Jacobson; Michael H Davidson
Statin safety: an assessment using an administrative claims database.
The American journal of cardiology 2006;97(8A):61C-68C.
2005: James M McKenney; Michael H Davidson; Joseph Saponaro; Paul D Thompson; Harold E Bays
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
Journal of cardiovascular pharmacology 2005;46(5):594-9.
2005: James M McKenney
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
The American journal of cardiology 2005;96(4A):60E-66E.
2005: James M McKenney
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2005;62(10):1033-47.
2004: James Shepherd; Donald B Hunninghake; Philip Barter; James M McKenney; Howard G Hutchinson
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Atherosclerosis. Supplements 2004;5(3):115-23.
2004: James M McKenney
Optimizing LDL-C lowering with statins.
American journal of therapeutics 2004;11(1):54-9.
2003: Harold E Bays; James M McKenney; Carlos A Dujovne; Helmut Schrott; Michael J Zema; Jack Nyberg; Diane E MacDougall
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
The American journal of cardiology 2003;92(5):538-43.
2003: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The American journal of cardiology 2003;92(2):152-60.
2003: James M McKenney
Potential nontraditional applications of statins.
The Annals of pharmacotherapy 2003;37(7-8):1063-71.
2003: James M McKenney
Pharmacologic characteristics of statins.
Clinical cardiology 2003;26(4 Suppl 3):III32-8.
2003: James Shepherd; Donald B Hunninghake; Philip Barter; James M McKenney; Howard G Hutchinson
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
The American journal of cardiology 2003;91(5A):11C-17C; discussion 17C-19C.
2003: James M McKenney; Peter H Jones; M Angeli Adamczyk; Valerie A Cain; Brian S Bryzinski; James W Blasetto
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Current medical research and opinion 2003;19(8):689-98.
2001: James M McKenney; L S McCormick; Ernst Schaefer; DM Black; M L Watkins
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
The American journal of cardiology 2001;88(3):270-4.
2001: James M McKenney
Achieving blood lipid goals in patients with coronary artery disease.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2001;58(5):415-9.
2000: John R Guyton; Michael A Blazing; J Hagar; Moti L Kashyap; Robert H Knopp; James M McKenney; D T Nash; S D Nash
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Archives of internal medicine 2000;160(8):1177-84.
1998: Michael J Koren; D G Smith; Donald B Hunninghake; Michael H Davidson; James M McKenney; Stuart R Weiss; Helmut Schrott; R W Henley; P Tresh; Richard McLain; RG Bakker-Arkema; DM Black
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
PharmacoEconomics 1998;14(1):59-70.
1998: James M McKenney; L S McCormick; S Weiss; Michael J Koren; S Kafonek; DM Black
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
The American journal of medicine 1998;104(2):137-43.
1998: James M McKenney
The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines.
PharmacoEconomics 1998;14 Suppl 3():19-28.
1998: D F Volles; James M McKenney; W G Miller; D Ruffen; D Zhang
Analytic and clinical performance of two compact cholesterol-testing devices.
Pharmacotherapy 1998;18(1):184-92.
1995: James M McKenney; J D Proctor; J T Wright; R J Kolinski; Ronald K Elswick; J S Coaker
The effect of supplemental dietary fat on plasma cholesterol levels in lovastatin-treated hypercholesterolemic patients.
Pharmacotherapy 1995;15(5):565-72.
1994: James M McKenney; J D Proctor; S Harris; V M Chinchili
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
JAMA : the journal of the American Medical Association 1994;271(9):672-7.
1993: James M McKenney
Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.
Pharmacotherapy 1993;13(4):340-52.
1993: James M McKenney
An evaluation of cholesterol screening in community pharmacies.
American pharmacy 1993;NS33(7):34-40.
1993: James M McKenney
New guidelines for managing hypercholesterolemia. National Cholesterol Education Program.
American pharmacy 1993;NS33(7):24-32.
1993: James M McKenney; D F Fary; G Miller; J D Proctor; V M Chinchili
An evaluation of two compact analyzers used for lipid analysis.
The Journal of family practice 1993;36(5):526-33.
1993: W Greg Miller; James M McKenney; M R Conner; V M Chinchilli
Total error assessment of five methods for cholesterol screening.
Clinical chemistry 1993;39(2):297-304.
1992: James M McKenney; M D Barnett; J T Wright; J P Proctor
Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
Archives of internal medicine 1992;152(9):1781-7.
1991: James M McKenney; J T Wright; G M Katz; R P Goodman
The effect of phenylpropanolamine on 24-hour blood pressure in normotensive subjects administered indomethacin.
DICP : the annals of pharmacotherapy 1991;25(3):234-9.
1991: M Moser; P A Abraham; W M Bennett; N Brachfeld; R P Goodman; James M McKenney; J W Hollifield; W M Kirkendall; K C Lasseter; A S Leon
The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
Clinical pharmacology and therapeutics 1991;49(3):322-9.
1989: J T Wright; James M McKenney; A M Lehany; D L Bryan; L W Cooper; C M Lambert
The effect of high-dose short-term ibuprofen on antihypertensive control with hydrochlorothiazide.
Clinical pharmacology and therapeutics 1989;46(4):440-4.
1988: James M McKenney
The questions are when and how to treat, not whether to treat, hypercholesterolemia.
Clinical pharmacy 1988;7(8):605-7.
1988: B J Jones; James M McKenney; J T Wright; R P Goodman
Effects of diltiazem hydrochloride on glucose tolerance in persons at risk for diabetes mellitus.
Clinical pharmacy 1988;7(3):235-8.
1988: James M McKenney
Lovastatin: a new cholesterol-lowering agent.
Clinical pharmacy 1988;7(1):21-36.
1987: James M McKenney; J T Wright; R P Goodman; L Cooper; N Yunker; C Lambert
Effect of high-dose ibuprofen on 24-hour blood pressure in healthy women.
Drug intelligence & clinical pharmacy 1987;21(6):517-21.
1986: R P Goodman; J T Wright; C O Barlascini; James M McKenney; C M Lambert
The effect of phenylpropanolamine on ambulatory blood pressure.
Clinical pharmacology and therapeutics 1986;40(2):144-7.
1986: James M McKenney; R P Goodman; J T Wright; N Rifai; D G Aycock; M E King
The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins.
Pharmacotherapy 1986;6(4):179-84.
1985: James M McKenney; R P Goodman; J T Wright
Use of antihypertensive agents in patients with glucose intolerance.
Clinical pharmacy 1985;4(6):649-56.
1985: L C Winship; James M McKenney; J T Wright; J H Wood; R P Goodman
The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics.
Pharmacotherapy 1985;5(1):16-9.